bliss gvs pharma has accepted the resignation of Sachin Saboo, General Manager – Regulatory and Clinical, effective July 24, 2026. The Mumbai-based pharmaceutical manufacturer disclosed the departure to the National Stock Exchange of India Limited and BSE Limited on July 24, 2026. Saboo, identified as Senior Management Personnel under SEBI regulations, submitted his resignation letter on April 30, 2026, citing an intent to move in a direction that aligns more closely with his professional aspirations. The change marks an exit from a key regulatory role within the company’s senior management structure.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III. The filing also referenced SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. Aditi Bhatt, Company Secretary, signed the intimation letter addressed to the listing departments of both exchanges.

Resignation Details

The company confirmed that Saboo was relieved from his duties at the close of business hours on July 24, 2026. His resignation letter, dated April 30, 2026, expressed appreciation for the support received from management and colleagues during his tenure. Saboo committed to ensuring a smooth transition of responsibilities during his notice period.

The filing did not disclose any relationships between directors or provide a brief profile beyond the designation. The company stated that the resignation was voluntary and based on personal career considerations.

The Committee of Independent Directors (IDC) of Bliss GVS Pharma Limited has recommended the open offer made by Anupam Rasayan India Limited to acquire up to 26% of the company's expanded voting share capital. The offer targets 2,77,26,848 fully paid-up equity shares at a price of ₹299.00 per share, aggregating to a total consideration of ₹829,03,27,552.00. The IDC, in its meeting held on July 22, 2026, reviewed the pricing parameters and determined that the offer price is fair and reasonable in accordance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The open offer follows the execution of a share purchase agreement dated May 23, 2026, for the acquisition of 4,58,03,024 equity shares, representing 43.11% of the equity share capital. The offer price of ₹299.00 per share represents the highest of the applicable pricing parameters, which includes the volume weighted average market price of ₹247.55 per share on the National Stock Exchange for the 60 trading days preceding the public announcement. However, the IDC noted that the closing market prices on BSE and NSE on July 17, 2026, were ₹482.50 and ₹483.50 per share respectively, which are higher than the offer price.

The committee, comprising Mr. Nandkumar Kashinath Chodankar as Chairperson and members Ms. Shilpa Vinodkumar Bhatia, Mr. Vijayanarayanan Mahadevan, and Mr. Deepak Rameshchandra Shah, unanimously approved the recommendation. SBI Capital Markets Limited is the manager to the open offer, and M/s. Swati Kedar Kothari & Co., Chartered Accountants, certified the offer price. The IDC advised public shareholders to independently evaluate the market performance and their investment objectives before tendering shares.

Tentative Schedule of the Open Offer

The tendering period opens on July 28, 2026, and closes on August 10, 2026. The offer is not conditional upon any minimum level of acceptance. Anupam Rasayan India Limited has opened an escrow account with Axis Bank Limited and deposited ₹160 crore as part of the financial arrangements for the offer.